对细菌反应的药物释放平台用于局部治疗细菌性阴道炎
Chuying Feng1, Chen Sun1, Emmanuel A Ho1,2
1School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, Ontario, Canada.
Nanotechnology
|August 20, 2024
概括
一个新型的细菌响应性脂质体平台可在需求时为细菌性阴道炎 (BV) 治疗提供药物. 这种有针对性的方法可以通过在检测到特定病原体 (如Gardnerella vaginalis) 时才释放药物来预防BV,从而最大限度地减少副作用.
科学领域:
- 生物医学工程 生物医学工程
- 药物输送系统 药物输送系统
- 微生物学 微生物学
背景情况:
- 细菌性阴道炎 (BV) 是一种普遍存在的阴道感染,其特点是厌氧失生症,通常涉及Gardnerella vaginalis (G. vaginalis).
- BV复发显著影响女性的健康,增加了早产,盆腔炎症和性传播感染的风险.
- 目前的阴道内疗法缺乏特异性,并且可能由于持续释放药物而引起副作用.
研究的目的:
- 开发和评估一种新型细菌响应性脂质体平台,用于按需预防和治疗BV.
- 创建一种药物输送系统,专门释放药物以应对主要BV病原体G. vaginalis.
- 通过有针对性,对刺激有反应的药物释放,尽量减少与传统BV治疗相关的副作用.
主要方法:
- 制备和表征四种脂质体配方.
- 基于药物释放概况,对G. vaginalis和L. crispatus (L. crispatus) 的脂质体反应的评估.
- 在 Vaginolysin 的存在下,药物释放动力学的评估,这是一种由 G. vaginalis 分泌的毒素.
主要成果:
- 脂质体配方表现出持续的药物释放 (46.7%51.8%超过3-5天),特别是对G. vaginalis.的反应.
- 在L. crispatus的存在下观察到最小的药物释放,这表明响应系统的高特异性.
- 该平台展示了特定于病原体的按需药物释放能力.
结论:
- 开发的细菌响应性脂质体平台为BV预防和治疗提供了一种新的,有针对性的方法.
- 这种按需药物递送系统有潜力显著提高治疗疗效,减少BV患者的副作用.
- 这项创新技术代表了管理BV和改善妇女生殖健康的有希望的进步.
相关概念视频
01:18Surface Membrane Barriers
1.1K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.1K
01:30Lytic Cycle of Bacteriophages
70.5K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.5K
00:57Antibiotic Selection
52.6K
Overview
52.6K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:30Bacterial Signaling
31.9K
Bacterial signaling can occur within bacteria (intracellular) or between bacteria (intercellular). At times, a group of bacteria behaves like a community. To achieve this, they engage in quorum sensing, the perception of higher cell density that causes changes in gene expression. Quorum sensing involves both extracellular and intracellular signaling. The signaling cascade starts with a molecule called an autoinducer (AI). Individual bacteria produce AIs that move out of the bacterial cell...
31.9K